Molecular characterization of an Italian series of sporadic GISTs
作者： P. Origone , , S. Gargiulo , L. Mastracci , A. Ballestrero
DOI: 10.1007/S10120-012-0213-Y
关键词:
摘要: Purpose Gastrointestinal stromal tumors (GISTs) are mesenchymal of the gastrointestinal tract. Most (80 %) contain activating mutations in KIT receptor tyrosine kinase, roughly 10 % platelet-derived growth factor receptor-alpha (PDGFRA). In a small subset, BRAF an alternative molecular pathway. GISTs respond well to imatinib, but low response is seen patients with wild-type or PDGFRA. Resistance has also been reported as result downstream effectors such BRAF.
springer.com
core.ac.uk
paperity.org
elsevier.com参考文章(22)
O Yerci, G Filiz, S B Adim, O Kanat, Simultaneous occurrence of synchronous and metachronous tumors with gastrointestinal stromal tumors. Bratislavské lekárske listy. ,vol. 112, pp. 623- 625 ,(2011)
George D Demetri, Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development. Hematology-oncology Clinics of North America. ,vol. 16, pp. 1115- 1124 ,(2002) , 10.1016/S0889-8588(02)00052-7
Kazuhiko Ezoe, Stuart A Holmes, Lingling Ho, Christopher P Bennett, Jean L Bolognia, Louise Brueton, John Burn, Rafael Falabella, Emilia M Gatto, Norihisa Ishii, Celia Moss, Mark R Pittelkow, Elizabeth Thompson, K Anne Ward, Richard A Spritz, Novel Mutations and Deletions of the KIT (Steel Factor Receptor) Gene in Human Piebaldism American Journal of Human Genetics. ,vol. 56, pp. 58- 66 ,(1995)
Isabelle Hostein, Nicolas Faur, Charlotte Primois, Frédérique Boury, Jérome Denard, Jean-François Emile, Pierre-Paul Bringuier, Jean-Yves Scoazec, Jean-Michel Coindre, BRAF Mutation Status in Gastrointestinal Stromal Tumors American Journal of Clinical Pathology. ,vol. 133, pp. 141- 148 ,(2010) , 10.1309/AJCPPCKGA2QGBJ1R
Jeremy R. Parfitt, Cathy J. Streutker, Robert H. Riddell, David K. Driman, Gastrointestinal stromal tumors: a contemporary review. Pathology Research and Practice. ,vol. 202, pp. 837- 847 ,(2006) , 10.1016/J.PRP.2006.08.006
Katerina Kontogianni-Katsarou, Euthimios Dimitriadis, Constantina Lariou, Evi Kairi-Vassilatou, Nikolaos Pandis, Agatha Kondi-Paphiti, KIT exon 11 codon 557/558 deletion/insertion mutations define a subset of gastrointestinal stromal tumors with malignant potential. World Journal of Gastroenterology. ,vol. 14, pp. 1891- 1897 ,(2008) , 10.3748/WJG.14.1891
Yusuke Kuwahara, Ayumu Hirata, Hideaki Miwa, Satoru Munakata, Shuji Ueda, Yuzuru Kanakura, Motohiko Maruno, Tadashi Hongyo, Taisei Nomura, Katsuyuki Aozasa, Epstein-Barr virus associated B-cell lymphoma of brain developing in myelodysplastic syndrome with c-kit mutation (Try-557 -->stop). American Journal of Hematology. ,vol. 65, pp. 234- 238 ,(2000) , 10.1002/1096-8652(200011)65:3<234::AID-AJH10>3.0.CO;2-E
A Agaimy, L M Terracciano, S Dirnhofer, L Tornillo, A Foerster, A Hartmann, M P Bihl, V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours Journal of Clinical Pathology. ,vol. 62, pp. 613- 616 ,(2009) , 10.1136/JCP.2009.064550
Christopher L. Corless, Christine M. Barnett, Michael C. Heinrich, Gastrointestinal stromal tumours: origin and molecular oncology. Nature Reviews Cancer. ,vol. 11, pp. 865- 878 ,(2011) , 10.1038/NRC3143
Jerzy Lasota, Agnieszka Dansonka-Mieszkowska, Leslie H Sobin, Markku Miettinen, A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential Laboratory Investigation. ,vol. 84, pp. 874- 883 ,(2004) , 10.1038/LABINVEST.3700122